drugset / Trial / NCT00954356

Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

NCT00954356 ↗

Phase 2 Completed 61 enrolled Xenon Pharmaceuticals Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this trial is to determine if XPF-001 is effective for the treatment of pain following third-molar/wisdom tooth extraction.

Timeline

Start
2009-09
Primary completion
2009-11
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject XPF-001 Unknown 500 mg Oral

Indications

No indication recorded.